U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Obesity and Metabolism Research: Davis, CA
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Laboratories
                        Bennett Group
                                    Huang Group
                                    Keim Group
                                    Laugero Group
                                    Newman GroupSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Pacific West Area Davis, California Western Human Nutrition Research Center Obesity and Metabolism Research Research Publications at this Location





- ARS National Programs
- Search for a scientific manuscript
- Search for a research project
- ARS Software
- Programs and Projects
- Collaborations
- Subjects of Investigation
- Publications

Title:   Author  item
                                            HAVENS, PETER - University Of Wisconsinitem
                                            HAZRA, ROHAN - National Institutes Of Health (NIH)item
                                            Stephensen, Charlesitem
                                            KISER, JENNIFER - University Of Coloradoitem
                                            FLYNN, PATRICIA - St Jude Children’s Research Hospitalitem
                                            WILSON, CRAIG - University Of Alabamaitem
                                            RUTLEDGE, BRANDY - Westat Incitem
                                            BETHEL, JAMES - Westat Incitem
                                            PAN, CYNTHIA - University Of Wisconsinitem
                                            Woodhouse, Leslieitem
                                            Van Loan, Martaitem
                                            LUI, NANCY - Westat Incitem
                                            LUJAN-ZILBERMANN, JORGE - University Of South Floridaitem
                                            BAKER, ALYNE - Tulane Universityitem
                                            KAPOGIANNIS, BILL - National Institutes Of Health (NIH)item
                                            GORDON, CATHLEEN - Brown Universityitem
                                            MULLIGAN, KATHLEEN - University Of California
  Submitted to: Antiviral Therapy
                                    Publication Type: Peer Reviewed Journal
                                    Publication Acceptance Date: 2/4/2014
                                    Publication  Date: 2/17/2014
                                    Citation: Havens, P.L., Hazra, R., Stephensen, C.B., Kiser, J., Flynn, P.M., Wilson, C.M., Rutledge, B., Bethel, J., Pan, C., Woodhouse, L.R., Van Loan, M.D., Lui, N., Lujan-Zilbermann, J., Baker, A., Kapogiannis, B.G., Gordon, C.M., Mulligan, K. 2014. Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youth treated with tenofovir disoproxil fumarate. Antiviral Therapy. DOI: 10.3851/IMP2755.Interpretive Summary: Tenofovir (TDF) is an antiretroviral drug associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor-23 causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D binding protein (VDBP) binds to 1,25-OH(2)D, decreasing biologic activity, and is elevated in persons with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youth treated with combination antiretroviral therapy (cART)containing or not containing TDF. A randomized controlled trial in HIV+ youth ages 18-25 years enrolled participants based on cART treatment with TDF (TDF, N=118) or without TDF (n-TDF, N=85) and randomized within those groups to VITD (50,000 IU every four weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was +7.7 pg/ml in the TDF/VITD group, compared to -1.7 (no-TDF/VITD, p=0.010); -1.3 (TDF/PL, p=0.006); and +1.1 (no-TDF/PL, p=0.035). These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youth
                                Technical Abstract: Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor-23 causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D binding proetin (VDBP) binds to 1,25-OH(2)D, decreasing biologic activity, and is elevated in persons with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youth treated with combination antiretroviral therapy (cART)containing or not containing TDF. A randomized controlled trial in HIV+ youth ages 18-25 years enrolled participants based on cART treatment with TDF (TDF, N=118) or without TDF (n-TDF, N=85) and randomized within those groups to VITD (50,000 IU every four weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean chnage in FGF23 from baseline to week 12 was +7.7 pg/ml in the TDF/VITD group, compared to -1.7 (no-TDF/VITD, p=0.010); -1.3 (TDF/PL, p=0.006); and +1.1 (no-TDF/PL, p=0.035). These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youth


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov